Dr. Engerman is an internationally recognized researcher that developed critical animal models to study diabetic retinopathy. One highlight of his career focused on prospective research in dogs to determine the progression of diabetic retinopathy if glycemic control was varied. His research found that retinopathy was preventable with good glycemic control but tends to be resistant even at early stage of disease before multiple aneurysms occur. In another study, Dr. Engerman found that in dogs with poor glycemic control the development of microvascular complications was promoted. However, with better glycemic control a reduction in the severity was observed. In combination this research has been cited over 1000 times.
Progression of incipient retinopathy during good glycemic control
Relationship of microvascular disease in diabetes to metabolic control
Dr. Engerman collaborated with global drug company, Pfizer Inc. to research the drug, Sorbinil, currently being used for treatment outside of the U.S. for diabetic complications including neuropathy and retinopathy.
Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs
Capillary basement membrane in retina, kidney and muscle of diabetic and galactosemic dogs and its response to 5 years aldose reductase inhibition
Nerve conduction and aldose reductase inhibtion during 5 years diabetes or galactosemia in dogs
Retinal polyol and myo-inositol in galactosemic dogs given an aldose reductase inhibitor
PhD 1964, University of Wisconsin, Madison, WI
MS 1959, Zoology, University of Wisconsin, Madison, WI
BS 1951, University of Wisconsin, Madison, WI